Zyntha is a patient-driven intelligence platform for brain-tumor communities — patients, caregivers, and clinicians. We monitor over a thousand sources of oncology research from around the world, surface what actually matters for your tumor type, and send it to you every other week in plain language. With sources cited.
Brain-tumor news lands differently depending on who you are. The digest is shaped for each.
Recent research that affects the treatments and trials available to you — explained in plain language, sources always cited.
Practical updates without the noise. What's changed, what it might mean for treatment, and what to watch for next visit.
A weekly second pair of eyes on neuro-oncology. Phase results, guideline updates, molecular and trial-design signals — across the world's literature.
A four-step pipeline runs continuously in the background. By the time a story reaches your inbox, it has been read, scored, summarized, and cited.
PubMed, EuropePMC, NEJM, JCO, JAMA Oncology, Lancet Oncology, Nature Cancer, STAT, Endpoints, hospital newsrooms (MSK, MD Anderson, Cleveland Clinic, Dana-Farber, 71+ NCI-designated centers), conference proceedings, ASCO, ASH, SNO, the FDA, and the ClinicalTrials.gov registry. Across journals, news outlets, and trial registries — every few hours.
Every paper, news article, and trial is read against a brain-tumor-specific rubric and tagged by tumor type, molecular subtype, evidence level (Phase 3 / Phase 2 / preclinical / review), and treatment category. Off-topic content and incidental keyword hits are filtered out before anything gets near your inbox.
Each item becomes a short summary, with the key findings as bullets and a "what this means" sentence translating the research into clinical or patient-facing implications. Compliance-reviewed copy. Source always cited and clickable.
The digest lands every other Sunday morning. Personalized to the tumor portal you pick at signup, with the option to switch portals or unsubscribe at any time. One email. No tracking pixels selling you anything.
A real entry from a recent issue. Title, summary, key findings, what it means, source. That's it.
The INDIGO trial demonstrated that vorasidenib, an oral IDH1/2 inhibitor, more than doubled progression-free survival compared with placebo in patients with recurrent IDH-mutant grade 2 glioma after surgery.
Each tumor type has its own newsletter, its own keyword model, and its own trial pipeline. You pick which one shows up in your inbox.
A brain-tumor community is one of the most personal spaces a person ever joins. Every architectural decision starts from the assumption that the trust we ask for is real.
The full Zyntha platform — community, in-app digest, personal health tracking, trial matching — opens soon. Subscribe now and the first edition lands in your inbox today.